Making multispecific capacity of antibodies into a precision medicine tool
Behind the scenes of our work to adapt an agonistic antibody with any type of drug cargo in order for us to improve the impact on the immune system and thereby therapeutic efficacy.
Beyond the Taste: A Multifunctional Gustatory Interface for Tongue Cancer Patients
Extensive surgical procedures involving flap reconstruction impact the taste perception for tongue cancer patients, highlighting the need for innovative approaches to dysgeusia.
Pectolinarigenin inhibits bladder urothelial carcinoma cell proliferation by regulating DNA damage/autophagy pathways
Pectolinarigenin (PEC) from herbal medicine targets DNA topoisomerase II alpha (TOP2A) in bladder cancer (BLCA), causing DNA damage and blocking cell division. It inhibits autophagy, boosting its effectiveness. Combined with gemcitabine, PEC more effectively halts BLCA growth.
Melatonin inhibits bladder tumorigenesis by suppressing PPARγ/ENO1-mediated glycolysis
Melatonin may help fight bladder cancer (BLCA) by slowing cancer cell energy production and increasing chemotherapy effectiveness, by targeting ENO1 to enhance gemcitabine’s impact and involving reactive oxygen species and PPARγ regulation. This suggests new methods for improving BLCA treatment.
Conditional reprogramming: Modeling urological cancer and translation to clinics
Patient-derived conditional reprogramming (CR) lets cells grow indefinitely, aiding in studying cancer, developing treatments, and advancing personalized medicine. This approach shows promise for improving urological cancer treatment.
Simvastatin induces cell cycle arrest and inhibits proliferation of bladder cancer cells via PPARγ signalling pathway
Simvastatin, a drug for heart disease by lowering cholesterol, also slows bladder cancer (BLCA) growth. It stops BLCA cells from multiplying by activating PPARγ, a fatty aicd/lipid metabolism pathway. This effect can be reversed with PPARγ inhibitors.
MYBL2 promotes proliferation and metastasis of bladder cancer through transactivation of CDCA3
Our research reveals that MYBL2, a gene-regulating protein, is elevated in bladder cancer (BLCA) and linked to worse patient outcomes. It boosts BLCA growth and spread by activating the CDCA3 gene, working with FOXM1 to enhance cancer traits. This identifies MYBL2 as a key promoter of BLCA.
Non-invasive diagnosis and surveillance of bladder cancer with driver and passenger DNAmethylation in a prospective cohort study
We studied DNA methylation markers in urine to enhance bladder cancer detection and classification. Our findings could transform non-invasive diagnosis and monitoring of this cancer and potentially other types as well, leading to major advances in cancer management with less invasive techniques.
Integrative single cell atlas revealed intratumoral heterogeneity generation from an adaptive epigenetic cell state in human bladder urothelial carcinoma
A subgroup of bladder cancer cells marked by TM4SF1 expression is a key source of tumor diversity (ITH). These cells, which show stem-cell features and foster various cell types within the tumor, are linked to more advanced cancer stages and poorer outcomes.
Unveiling the Mechanisms Behind Cancer Aggressiveness: How Epichaperomes Drive Cellular Plasticity
What makes cancer so aggressive and adaptable? Our latest research uncovers a hidden mechanism within cells—specialized protein networks called epichaperomes. These structures help cancer cells survive and thrive, reactivating developmental pathways and fueling unchecked growth.
A novel germline EGFR variant p.R831H causes predisposition to familial CDK12-mutant prostate cancer with tandem duplicator phenotype
This study is the first report identifying a pathogenic EGFR germline mutation in prostate cancer, suggesting venues for germline screening, non-invasive diagnosis and monitoring in clinical practice.